About Private Peptides

The name

Private Peptides holds my notes on published research on AOD-9604, MOTS-c and retatrutide. The private part is the quiet room a difficult result deserves. The papers are public; there are no confidential findings or privileged access behind this name.

The passages that undo an attractive story draw me further into a paper. A trial misses its endpoint. A human paper measures a marker without administering anything. A molecule reaches several receptors with surprisingly uneven potency. There is more to think about in those details than in a list of promised benefits.

This site is informational and provides no medical advice. It sells, ships, prescribes and books nothing. Clinical decisions require a licensed healthcare provider’s assessment.

The arguments worth having

I have a soft spot for experiments that expose their own weaknesses. The AOD-9604 receptor-knockout work in obese mice and beta3-AR knockout mice is a good example: remove the receptor and the chronic weight effect disappears, while an acute energy effect survives. That result gives a mechanism texture even though the obesity program disappointed.

With MOTS-c, I arrived interested in the exercise claims and ended more interested in the stress-driven journey to the nucleus observed in human and mouse cell cultures. With retatrutide, the liver-fat substudy makes me look beyond the body-weight headline. These preferences are opinions about the published results, and the unresolved human safety questions remain unresolved.

Corrections

A misdescribed population or endpoint can change the meaning of a whole paragraph. A precise correction with a paper attached will bring me back to the passage, especially where a conclusion outruns its source. The contact page gives the mailbox and the details that make a correction usable.

The reading list includes the sources discussed here. Personal medical questions, treatment suitability and requests for supplies fall outside this site’s scope.